German biotech Kupando raises €10M more to take its innate immunity drug into the clinic
An extension to the company’s Series A brings total funding to €23 million and clears the path for the first human trial of KUP101, a dual TLR agonist targeting solid tumours and drug-resistant infections. Most immunotherapy research in oncology has concentrated on the adaptive immune system, the learned, antibody-generating machinery that checkpoint inhibitors like pembrolizumab […]<br /> This story continues at The Next Web [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
Lumai Raises $10M+ to Revolutionize AI Compute with Optical Processing
In a major leap forward for the future of artificial intelligence infrastructure, Lumai, the Oxford-born startup pioneering 3D optical computing, has raised more than $10 million in a fresh funding ro [...]
German Bionic’s new Apogee Ultra exoskeleton can lift up to 80 pounds and help with walking
German Bionic, the robot exoskeleton startup behind the lightweight Apogee exosuit, just revealed the Apogee Ultra at CES 2025 in Las Vegas. This powered exoskeleton is intended to help people complet [...]
German Commons shows that big AI datasets don’t have to live in copyright limbo
German Commons is now the largest openly licensed German text dataset, offering a foundation for building legally compliant German language models.<br /> The article German Commons shows that bi [...]
Pfizer, drug companies make 'no commitments' to White House about lowering drug prices
Cheaper pharmaceuticals won’t be on shelves any time soon, says the CEO of Pfizer. That’s despite an executive order signed last month declaring a war on drug prices, which at one point President [...]